At JaxBio, we are revolutionising the way cancer is diagnosed and managed by making cancer detection simpler, quicker, and more precise, and we're doing that through our innovative blood test technology. Our unique blood test offers advantages over traditional methods and traditional liquid biopsies. Based on its high sensitivity together with low cost and simplicity, we can deliver results faster with improved accuracy. By improving screening and early detection capabilities for cancer, healthcare providers and patients can now make better informed decisions sooner when time is of the essence. We use novel artificial intelligence (AI) algorithms to identify sets of biomarkers that are effective in detecting various types and subtypes of cancer at different stages. Our tests aren't just for initial diagnosis; they're also valuable tools for monitoring disease status and predicting how well a patient will respond to therapy. Our platform technology can also be used in a range of diseases, including various types of cancer, neurodegenerative diseases, and heart diseases. Connect with us to learn more.
| Website | http://www.jaxbio.com |
| Employees | 12 (8 on RocketReach) |
| Founded | 2022 |
| Industry | Medical and Diagnostic Laboratories |
| Keywords | Liquid Biopsy, Oncology Testing, Cancer Diagnostics, Oncology Diagnostics, Precision Oncology, Cancer Biomarkers, Non-Invasive Diagnostics, Early Cancer Detection, In-Vitro Diagnostics, Innovative Diagnostics, Molecular Diagnostics, Cancer Screening, Cancer Treatment, Clinical Diagnostics, Diagnostic Testing, Medical Diagnostics, Disease Diagnostics, Cancer Research |
| Competitors | Roche, Thermo Fisher Scientific, Merck Group, Agilent Technologies, Illumina, PerkinElmer, Inc., Bio-Rad Laboratories, QIAGEN, New England Biolabs, Stilla Technologies +46 more (view full list) |
Looking for a particular JaxBio employee's phone or email?
Yael Michaeli is the CTO of JaxBio.
8 people are employed at JaxBio.